A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

NCT07155668 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

87

Enrollment

INDUSTRY

Sponsor class

Conditions

Thyroid Eye Disease

Interventions

DRUG: VRDN-003
DEVICE: Autoinjector

Sponsor

Viridian Therapeutics, Inc.